The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...